Floatz logo

FULVESTRANT

Advanced Solid Malignancies

Carrick Therapeutics LimitedSmall moleculePhase 1/2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Advanced Solid Malignancies cohort.

Asset / SponsorPhaseRating
Durvalumab
AstraZeneca
Phase 3B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
AstraZeneca
Phase 3B
prj1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2CCC
IMARADENANT
AstraZeneca
Phase 1CCC
Tak-228
Millennium Pharmaceuticals, Inc.
Phase 1CCC

View all 50 →

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →